Item 5. Other Information
Item 5. Other Information
Rule 10b5-1 Trading Plans
On February 26, 2024 , Julie McHugh , a member of our Board , entered into a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (a “10b5-1 Plan”), providing for the potential sale of up to 2,500 shares of our common stock on May 28, 2024.
On February 27, 2024 , Heinz Mäusli , a member of our Board , entered into a 10b5-1 Plan providing for the potential sale of up to 25,692 shares of our common stock, including shares obtained from the exercise of vested stock options covered by the 10b5-1 Plan, between May 28, 2024 and September 30, 2024.
On March 1, 2024 , Paul Blanchfield , our President , entered into a 10b5-1 Plan providing for the potential sale of up to 7,263 shares of our common stock, between May 31, 2024 and March 5, 2025. Pursuant to the 10b5-1 Plan, Mr. Blanchfield will also make a gift of 355 shares of common stock on November 14, 2024.
On March 1, 2024 , Daniel Niedzwiecki , our Chief Administrative Officer, General Counsel and Corporate Secretary , entered into a 10b5-1 Plan providing for the potential sale of up to 15,373 shares of our common stock, between May 30, 2024 and August 30, 2024.
39
Table of Contents
On March 13, 2024 , Mary Anne Heino , a member of our Board , entered into a 10b5-1 Plan. The plan provides for the sale of shares of our common stock between August 2, 2024 and March 31, 2025 in an amount (i) sufficient to cover tax withholding obligations in connection with the potential vesting and settlement of up to 117,006 outstanding RSUs and PSUs plus (ii) an additional number of shares necessary to result in approximate net sale proceeds of $2,000,000 in the aggregate.
40
Table of Contents
Item 6. Exhibits
INCORPORATED BY REFERENCE
EXHIBIT
NUMBER DESCRIPTION OF EXHIBITS FORM FILE
NUMBER EXHIBIT FILING
DATE
10.1* First Amendment to License and Collaboration Agreement (PNT-2002), dated as of January 31, 2024, by and between POINT Biopharma, Inc. and Lantheus Two, LLC and Lantheus Medical Imaging, Inc.
31.1* Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a).
31.2* Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).
32.1** Certification pursuant to 18 U.S.C. Section 1350.
101.INS* Inline XBRL Instance Document
101.SCH* Inline XBRL Taxonomy Extension Schema Document
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Filed herewith.
** Furnished herewith.
41
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LANTHEUS HOLDINGS, INC.
By: /s/ BRIAN MARKISON
Name: Brian Markison
Title: Chief Executive Officer
(Principal Executive Officer)
Date: May 2, 2024
LANTHEUS HOLDINGS, INC.
By: /s/ ROBERT J. MARSHALL, JR.
Name: Robert J. Marshall, Jr.
Title: Chief Financial Officer and Treasurer
(Principal Financial Officer)
Date: May 2, 2024
42
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.